-
In the past month, the good news that the API industry products have been approved continues!
Time of Update: 2022-12-30
The API industry is one of the core directions of new pharmaceutical manufacturing in China, with the dual growth of upgrading itself and undertaking the transfer of the global industrial chain, and the logical clarity of iterative development to a higher-end innovative drug CDMO (customized R&D and production).
-
CLAUDIN 18.2 fierce battle, who will be the first to break through the domestic pharmaceutical company?
Time of Update: 2022-12-30
In a phase III clinical trial published in mid-November, results showed that the study met the primary endpoint of PFS (progression-free survival) in 566 patients with CLDN18.
-
DuPont ion exchange resin auxiliary material CDE was successfully registered
Time of Update: 2022-12-30
Wilmington, Delaware, USA, December 5, 2022 DuPont (NYSE: DD) today announced that its ion exchange resin excipients AmberLite IRP69 and AmberLite™™ IRP70 have been registered in China CDE (Center for Drug Evaluation of the National Medical Products Administration), which will help meet local market demand for pharmaceutical and life science products.
-
CPHI & PMEC China 2022 Extension Announcement
Time of Update: 2022-12-30
Dear exhibitors, visitors and industry colleagues, In view of the recent severe situation of the prevention and control of the new crown pneumonia epidemic in China, in accordance with the relevant r
-
Cell therapy is coming to a harvest, and the Pharmacopoeia Commission intends to release a rapid microbial examination strategy for cell-based products
Time of Update: 2022-12-30
On December 1, 2022, the official website of the National Pharmacopoeia Commission once again released the public draft of the Law on Microbial Inspection of Cell Products, with a public period of 1
-
The information platform of the non-clinical safety evaluation research institution of drugs was put into operation
Time of Update: 2022-12-30
From the date of issuance of the circular, GLP institutions, relevant provincial drug administrations, and food and drug review and inspection centers of the State Medical Products Administration (hereinafter referred to as verification centers) shall log in to the GLP institution information platform and promptly fill in GLP institution information, GLP certification status, supervision and inspection results of GLP institutions, investigation and punishment of illegal acts, and other information.
-
104 varieties have been evaluated, and 4 varieties have been evaluated for the first time! Injection declaration accounted for 75%, Renhe Yikang, Hubei Xinghua, Tianjin Jinyao...
Time of Update: 2022-12-30
Figure 1 Notification/adoption trend from January 2022 to November 2022 Data source: PharmaIntelligence Data, PharmaIntelligence Consulting Review details In November, a total of 37 consistency evaluation acceptance numbers and 121 generic drug marketing application acceptance numbers were deemed to have passed the consistency evaluation, involving 104 varieties of 111 enterprises.
-
Digital intelligence empowers the production of key drugs to speed up and increase efficiency!
Time of Update: 2022-12-29
Recently, with the great increase in demand for analgesic and antipyretic and other therapeutic drugs, the workshops of pharmaceutical companies in many places have actively worked overtime to speed
-
The region's regional Chinese medicine pieces information traceability system has covered the whole city!
Time of Update: 2022-12-29
js?cdnversion='+~(-new Date()/36e5)];Chinese medicine pieces are one of the three pillars of China's traditional Chinese medicine industry, and the market size is becoming increasingly large under the background of aging population and consumption upgrading.
-
R&D investment continues to increase, and domestic pharmaceutical companies have begun to usher in a harvest period
Time of Update: 2022-12-29
js?cdnversion='+~(-new Date()/36e5)];In recent years, under the background of the intensification of pharmaceutical reform and the trend of innovation, the R&D investment of pharmaceutical companies is increasing year by year.
-
National Health Commission: All localities have set up special classes for rectifying "layer by layer"
Time of Update: 2022-12-04
Yesterday afternoon, the joint prevention and control mechanism of the State Council has held a video and telephone conference, the meeting made a specific interpretation of the 20 optimization measures, and also put forward corresponding work requirements for the implementation of the 20 measures, leading organs and relevant departments at all levels of epidemic prevention and control, leading cadres should learn one step ahead and take the lead in mastering.
-
Let the "light of the Internet" light up environmental protection, and the 2022 Vision Conference - Autumn Exhibition ended successfully
Time of Update: 2022-12-04
7 summit forum carousel, professional and in-depth UP Preferred petrochemical wastewater treatment, solid alternative fuels, high-quality development of solid waste recycling, fluid low-carbon intelligent technology, sludge disposal, power battery recycling, VOCs monitoring and governance 7 hot topics, experts and scholars, front-line engineers and enterprise representatives relay speeches, environmental protection knowledge points are sent intensively, worthy of N brushing!
-
Qinghai Province: 27 ethnic medicines are expected to be included in the Qinghai Provincial Medical Insurance Catalogue
Time of Update: 2022-12-04
The announcement shows that according to the adjustment provisions of the relevant ethnic drug list in Qinghai Province, the provincial medical insurance bureau conducted a preliminary review of the ethnic drugs declared for inclusion in the list, and publicized the list of drugs that passed the preliminary review.
-
In many places, a large number of good drugs will be included in medical insurance!
Time of Update: 2022-12-04
js?cdnversion='+~(-new Date()/36e5)];According to the relevant regulations of the National Health Insurance Administration, all provinces will gradually digest the supplementary medical insurance catalogue of the original province, and it is planned that all of them will be digested by the end of 2022, and the national drug catalogue will be unified next year.
-
Special Provisions on the Administration of Registration of Traditional Chinese Medicines for Public Solicitation (Draft for Comments)
Time of Update: 2022-12-04
In order to implement the "Opinions of the Central People's Republic of China/CPC Central Committee on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicine", follow t
-
The concept of Web 3.0 is active, and many pharmaceutical companies have actively laid out
Time of Update: 2022-12-04
Recently, the concept of Web 3. 0 is active, Wind data shows that as of the close of November 11, the Web 3. 0 index has risen by more than 13% in the past 5 days and more than 26% in the past 20 days
-
In the past month, new appointments of executives of multinational pharmaceutical companies have continued!
Time of Update: 2022-12-04
js?cdnversion='+~(-new Date()/36e5)];In recent years, affected by the drastic changes in the pharmaceutical industry, multinational pharmaceutical companies have begun to adjust their development strategies and talent structures on a large scale.
-
The pharmaceutical field has become the focus of institutional research, and these subdivisions have attracted attention!
Time of Update: 2022-12-04
(Image source: Pharma Network) Among them, the investor relations activity record form released by Mindray Medical on October 28, 2022 shows that the company was surveyed by 391 institutions on October 28, 2022, including QFII, insurance companies, others, fund companies, overseas institutions, securities companies, and sunshine private equity institutions.
-
Domestic pharmaceutical companies' APIs are accelerating to the sea, and the good news continues!
Time of Update: 2022-12-04
As a major producer and exporter of APIs, with the promotion of new policies for medical reform and the impact of global order transfer and other factors in recent years, the scale of China's API industry is expanding while the overseas expansion of APIs is also accelerating.
-
Under the wave of new infrastructure, domestic medical equipment companies will take great strides!
Time of Update: 2022-12-04
(Image source: Pharma Network) Under the wave of new infrastructure, domestic medical equipment companies will take great strides!
(Image source: Pharma Network) In the secondary market, the activity of the medical device sector has also increased significantly, with the sector rising more than 18% since the low, standing out among the entire pharmaceutical and medical sectors.
